Skip to main content

Table 1 DEGs in liver cancer samples compared with normal samples

From: Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis

DEGs Gene name
Upregulated CCNB1, CDKN3, CCNB2, ASPM, TOP2A, UBE2T, BIRC5, FAM83D, MDK, KIF4A, CDK1, FAM72A///FAM72D///FAM72B///FAM72C, TTK, ANLN, CENPF, NCAPG, PBK, PTTG1, AURKA, RACGAP1, GPC3, NUF2, PRC1, GINS1, GMNN, RRM2, MELK, NEK2, CDC20, IQGAP3, NDC80, DLGAP5, ECT2, HMMR, KIF20A, SULT1C2, RAD51AP1, IGF2BP3, CENPK, DTL, DUXAP10, HELLS, FLVCR1, TYMS, CAP2, MAD2L1, UHRF1, KIAA0101, MCM6, PRR11, BUB1B, ACSL4, PEG10, CRNDE, ROBO1, SLC35F6///CENPA, CD24, CTHRC1, CKAP2, RBM24.
Downregulated CLEC4M, CLEC4G, OIT3, FCN3, CYP2A6, TTC36, FOSB, CYP1A2, APOF, FOS, FCN2, MT1G, GLS2, GBA3, LCAT, CLEC1B, KCNN2, CXCL14, GLYAT, HGF, MARCO, CYP39A1, MT1X, GPM6A, HHIP, ANXA10, C8A, MT1M, TMEM27, GYS2, AKR1D1, HAMP, MT1F, PLAC8, CYP2B6, C7, KMO, MT1H, NAT2, SLC22A1, CYP2A7, CNDP1, MT1HL1, C3P1, BCO2, CRHBP, MT1E, GSTZ1, KCND3, SORL1, HAO2, ADH1B, CYP4A11, EGR1, ESR1, SLC25A47, CYP4A22///CYP4A11, GNMT, HGFAC, LINC01093, F9, SRPX, LINC00844, HEPN1///HEPACAM, SRD5A2, CYP2B7P///CYP2B6, MFSD2A, FLJ22763, FOLH1, BBOX1, SDS, BCHE, C9, SLC10A1, TSLP, LYVE1, MME, PGLYRP2, DCN, CYP3A4, CYP8B1, KBTBD11, GHR, CTH, CFHR4, AADAT, CXCL2, CYP26A1, C6, CETP, PDGFRA, FBP1, SERPINE1, RSPO3, PBLD, RDH16, SLCO1B3, IDO2, PZP, LPA, PCK1, AFM, ASPA, CLRN3, CNTN3, HPGD, ACSM3, LOC101928916///NNMT.
  1. A total of 60 upregulated DEGs and 108 downregulated DEGs were identified in the liver cancer tissues, compared with normal liver tissues. The hub genes were shown in boldface